Gazyva for Follicular Lymphoma (previously untreated) – Details


( Last Updated : November 16, 2018)
Generic Name:
Obinutuzumab
Project Status:
Complete
Therapeutic Area:
Follicular Lymphoma (previously untreated)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Gazyva
Project Line:
Reimbursement Review
Project Number:
PC0126-000
NOC Date:

Details


Strength:
25 mg/mL
Tumour Type:
Lymphoma
Indications:
Follicular Lymphoma (previously untreated)
Funding Request:
For the treatment of patients with previously untreated stage II bulky (>7cm), III or IV follicular lymphoma (FL)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.